The therapeutic agents flunarizine and lomerizine exhibit inhibitory activities against a variety of ion channels and neurotransmitter receptors. We have optimized their scaffolds to obtain more selective N-type calcium channel blockers. During this optimization, we discovered NP118809 and NP078585, two potent N-type calcium channel blockers which have good selectivity over L-type calcium channels. Upon intraperitoneal administration both compounds exhibit analgesic activity in a rodent model of inflammatory pain. NP118809 further exhibits a number of favorable preclinical characteristics as they relate to overall pharmacokinetics and minimal off-target activity including the hERG potassium channel.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2009.09.008DOI Listing

Publication Analysis

Top Keywords

n-type calcium
12
calcium channel
12
channel blockers
12
potent n-type
8
scaffold-based design
4
design synthesis
4
synthesis potent
4
calcium
4
channel
4
blockers therapeutic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!